Welcome to our dedicated page for SI-BONE news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on SI-BONE stock.
SI-BONE, Inc. (NASDAQ: SIBN) is a leading medical device company specializing in the development and commercialization of innovative, minimally invasive surgical implants for the treatment of musculoskeletal disorders, particularly those affecting the sacroiliac (SI) joint. The company's flagship product, the iFuse Implant System®, offers a less invasive alternative to traditional SI joint fusion surgery. This patented system has been used in over 25,000 procedures, providing a significant improvement in patient outcomes.
SI-BONE's portfolio includes a range of patented titanium implants and instruments specifically designed for sacroiliac fusion. Key products include iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite. These implants are employed in the management of sacroiliac joint dysfunction, adult spinal deformity, degeneration, and pelvic trauma.
The company has achieved several milestones in recent years. Notably, the iFuse Bedrock Granite implant received FDA clearance in May 2022 and was designated a Breakthrough Device due to its significant advantages over existing alternatives. Subsequently, the Centers for Medicare & Medicaid Services (CMS) adopted a New Technology Add-on Payment of up to $9,828 per procedure for this innovative implant.
SI-BONE is managed by an experienced leadership team with backgrounds in top-tier companies like Kyphon, Medtronic, and Inbone. This expertise has driven the company's growth and innovation in the orthopedic field.
In terms of financial performance, SI-BONE has shown robust growth. The company's annual revenue guidance has been increased to $164 million - $166 million, indicating an annual growth rate of approximately 18%-20%. This growth is fueled by the strong reception of new products and established partnerships with major healthcare providers, including compatibility with Medtronic's Solera® rods.
Since its inception in 2009, SI-BONE has supported over 3,000 surgeons in performing more than 80,000 sacropelvic procedures. The company's technologies are backed by a unique body of clinical evidence, including two randomized controlled trials and over 120 peer-reviewed publications.
For more information on SI-BONE and its range of products, visit the official website at www.si-bone.com.
SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, a leader in musculoskeletal disorder solutions, will participate in the 2023 Bank of America Merrill Lynch Global Healthcare Conference. The event features a management fireside chat on May 9, 2023, at 1:55 p.m. Eastern Time. A live webcast will be accessible via the company's website with a 90-day post-event archive available for replay.
SI-BONE, known for the iFuse Implant System, has pioneered minimally invasive surgical treatments for SI joint disorders since 2009. With nearly 80,000 procedures performed by over 3,000 surgeons, SI-BONE enjoys wide insurance coverage for these treatments. This position enables continued advancements in clinical research and the commercialization of new surgical solutions for pelvic disorders.
SI-BONE, Inc. (Nasdaq: SIBN), a leader in surgical solutions for musculoskeletal disorders, will report its Q1 2023 financial results on May 1, 2023, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. Interested investors can register for the call through the provided link. The company has established a strong market position with over 80,000 SI joint fusion procedures performed using its iFuse Implant System, backed by extensive research and insurance coverage. SI-BONE continues to innovate in clinical applications and expand its offerings for sacropelvic conditions.
SI-BONE, Inc. (Nasdaq:SIBN) reported a strong financial performance for Q4 and full year 2022, with worldwide revenue reaching $32.0 million in Q4 and $106.4 million for the full year, reflecting increases of 27% and 18%, respectively. U.S. revenue was $30.0 million in Q4 and $98.8 million for 2022, driven mainly by increased domestic case volumes. Despite a net loss of $11.2 million in Q4 and $61.3 million for the full year, the company's adjusted EBITDA loss improved by 54%. Looking ahead, SI-BONE expects 2023 revenue to be between $124 million and $127 million, with a projected gross margin of 80%.
SI-BONE, Inc. (Nasdaq: SIBN), a leader in musculoskeletal disorder solutions, will announce its fourth quarter 2022 financial results on February 27, 2023, after market close. The company also plans a conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via registration. Since launching the iFuse Implant System in 2009, over 75,000 SI joint fusion procedures have been performed by more than 3,000 surgeons. SI-BONE has achieved extensive coverage from various insurance payors for minimally invasive SI joint fusion procedures, enhancing its market position and supporting ongoing clinical research and new treatment developments.
SANTA CLARA, Calif., Jan. 9, 2023 — SI-BONE, Inc. (NASDAQ: SIBN) announced preliminary fourth quarter and fiscal year 2022 revenue. Fourth quarter revenue is expected between $31.7 and $31.9 million, a 26% increase year-over-year. U.S. revenue is projected at $29.8 to $29.9 million, up 28%. For 2022, worldwide revenue is anticipated between $106.1 and $106.3 million, reflecting an 18% increase. Cash and marketable securities are forecasted at $96 million as of December 31, 2022.
SI-BONE, Inc. (NASDAQ: SIBN) announced its participation in the 25th Annual Needham Growth Conference, set for January 12, 2023, at 11:45 a.m. ET. Management will host a virtual fireside chat during this event.
A live webcast will be accessible on the company’s website, with recordings available for at least 90 days afterward. SI-BONE specializes in surgical treatments for musculoskeletal disorders, notably the iFuse Implant System. Since its introduction in 2009, over 75,000 procedures have been performed, supported by extensive clinical research.
SI-BONE, Inc. (Nasdaq: SIBN) announced FDA clearance for iFuse Bedrock Granite, now indicated for use with various pedicle screw rods. This implant, introduced in May 2022, helps address complications in adult spinal deformity treatments, improving surgical outcomes. The expanded clearance allows surgeons to use preferred techniques while enhancing treatment options. CEO Laura Francis believes this will increase surgeon adoption of the device. Since its launch, iFuse has been a favored implant in pelvic fixation constructs.
FAQ
What is the current stock price of SI-BONE (SIBN)?
What is the market cap of SI-BONE (SIBN)?
What is SI-BONE, Inc.?
What is the iFuse Implant System®?
What products does SI-BONE offer?
How many procedures have used the iFuse Implant System®?
Who manages SI-BONE, Inc.?
What is the revenue guidance for SI-BONE in the latest fiscal year?
Has the iFuse Bedrock Granite implant received FDA clearance?
What clinical evidence supports SI-BONE’s technologies?
Where can I find more information about SI-BONE’s products?
What are the potential risks associated with the iFuse Implant System®?
